Neuronetics, Inc.
STIM US
STIM USNeuronetics, Inc.
United States Composite1.91
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.- Business
- Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Company News
NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting
Neuronetics And 3 Other Stocks Under $3 Insiders Are Buying
Director Robert Cascella Acquires 50,000 Shares of Neuronetics Inc (STIM)
Neuronetics to Present at the William Blair 44th Annual Growth Stock Conference
Neuronetics to Present at the William Blair 44th Annual Growth Stock Conference
Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents
Neuronetics Inc (STIM) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth Amidst Challenges
Q1 2024 Neuronetics Inc Earnings Call Transcript
Nasdaq Moves Lower; Great Lakes Dredge & Dock Shares Surge Following Upbeat Earnings
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
Neuronetics Inc (STIM) Reports Q1 2024 Earnings: Revenue Surpasses Estimates, Narrowing Losses
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics wins FDA clearance for device to treat adolescents with depression